US 12,226,617 B2
Integrated delivery device for continuous glucose sensor
James H. Brauker, Addison, MI (US); Mark A. Tapsak, Orangeville, PA (US); Sean T. Saint, San Diego, CA (US); Apurv Ullas Kamath, San Diego, CA (US); Paul V. Neale, San Diego, CA (US); Peter C. Simpson, Cardiff, CA (US); Michael Robert Mensinger, San Diego, CA (US); and Dubravka Markovic, San Diego, CA (US)
Assigned to Dexcom, Inc., San Diego, CA (US)
Filed by DexCom, Inc., San Diego, CA (US)
Filed on Dec. 20, 2021, as Appl. No. 17/556,761.
Application 12/536,852 is a division of application No. 10/789,359, filed on Feb. 26, 2004, granted, now 7,591,801, issued on Sep. 22, 2009.
Application 17/556,761 is a continuation of application No. 15/906,946, filed on Feb. 27, 2018, granted, now 11,246,990.
Application 15/906,946 is a continuation of application No. 14/830,568, filed on Aug. 19, 2015, granted, now 9,937,293, issued on Apr. 10, 2018.
Application 14/830,568 is a continuation of application No. 13/559,454, filed on Jul. 26, 2012, granted, now 9,155,843, issued on Oct. 13, 2015.
Application 13/559,454 is a continuation of application No. 13/180,396, filed on Jul. 11, 2011, granted, now 8,460,231, issued on Jun. 11, 2013.
Application 13/180,396 is a continuation of application No. 12/536,852, filed on Aug. 6, 2009, granted, now 7,976,492, issued on Jul. 12, 2011.
Prior Publication US 2022/0111148 A1, Apr. 14, 2022
Int. Cl. G16H 20/17 (2018.01); A61B 5/00 (2006.01); A61B 5/145 (2006.01); A61B 5/1486 (2006.01); A61M 5/14 (2006.01); A61M 5/172 (2006.01); A61M 5/315 (2006.01); A61M 11/00 (2006.01); A61M 15/00 (2006.01); A61M 37/00 (2006.01); G16H 10/40 (2018.01); G16H 40/63 (2018.01)
CPC A61M 5/31525 (2013.01) [A61B 5/0002 (2013.01); A61B 5/14532 (2013.01); A61B 5/14865 (2013.01); A61B 5/4839 (2013.01); A61M 5/1723 (2013.01); A61M 11/00 (2013.01); A61M 15/0001 (2014.02); G16H 10/40 (2018.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); A61B 5/1486 (2013.01); A61B 2560/0443 (2013.01); A61M 2005/1726 (2013.01); A61M 2205/18 (2013.01); A61M 2205/3303 (2013.01); A61M 2205/502 (2013.01); A61M 2205/52 (2013.01); A61M 2230/201 (2013.01)] 20 Claims
OG exemplary drawing
 
1. An integrated system for treating diabetes, the integrated system comprising:
a medicament delivery pen; and
a receiver operably connected to the medicament delivery pen to:
receive a signal from a glucose sensor indicative of a concentration of glucose of a user;
request user interaction validating a personalized therapy recommendation only when a potential clinical risk is determined to be present and not request user interaction validating the personalized therapy recommendation when a potential clinical risk is not determined to be present, the-personalized therapy recommendation being determined based on the concentration of glucose and based on an amount of medicament manually entered;
receive the user interaction validating the personalized therapy recommendation in response to the request; and
responsive to the user interaction validating the personalized therapy recommendation, cause the medicament delivery pen to administer an injection of the medicament.